Search

Your search keyword '"Amital, Howard"' showing total 1,366 results
Start Over Author "Amital, Howard"
1,366 results on '"Amital, Howard"'

155. Contributors

Author

Abdurakhmanov, Alexander, primary, Abu-Shakra, Mahmoud, additional, Afanasyeva, Marina, additional, Agmon-Levin, Nancy, additional, Albert, Paul J., additional, Almeida, Isabel, additional, Alves, Rute, additional, Amital, Howard, additional, Andrade, Paulo, additional, Antonelli, Alessandro, additional, Puccetti, Antonio, additional, Arango, María-Teresa, additional, Atzeni, Fabiola, additional, Baird, Alison E., additional, Balbir-Gurman, Alexandra, additional, Bashi, Tomer, additional, Batticciotto, Alberto, additional, Benucci, Maurizio, additional, Blank, Miri, additional, Bogdanos, Dimitrios P., additional, Bombardieri, S., additional, Borella, E., additional, Bosis, Samantha, additional, Bournia, Vasiliki Kalliopi, additional, Brandão, Mariana, additional, Braun-Moscovici, Yolanda, additional, Brender-Gotlieb, Neta, additional, Cainelli, Francesca, additional, Caldas, Cezar Augusto Muniz, additional, Campar, A., additional, Carvalheiras, Graziela, additional, Cervera, R., additional, Chapman, Joab, additional, Chastain, Emily M.L., additional, Claudio, Lunardi, additional, Cohen, Eytan, additional, Conti, Fabrizio, additional, Correia, J., additional, Carvalho, Jozélio Freire de, additional, Rossa, A. Della, additional, Detrick, Barbara, additional, Deutsch, Melanie, additional, Di Domenicantonio, Andrea, additional, Domeneghetti, M., additional, Domingues, Vital, additional, Doria, A., additional, Dow, Coad Thomas, additional, Dreyfus, David H., additional, Drouin, Elise E., additional, Dubaniewicz, Anna, additional, Durai, Malarvizhi, additional, Ebringer, Alan, additional, Ehrenfeld, Michael, additional, Elisa, Tinazzi, additional, Esposito, Susanna, additional, Fallahi, Poupak, additional, Faria, Raquel, additional, Farinha, Fátima, additional, Ferrannini, Ele, additional, Ferrari, Silvia Martina, additional, Ferreira, Alvaro, additional, Ferrão, C., additional, Garg, Ravindra Kumar, additional, Gatto, M., additional, Ghirardello, A., additional, Giovanna, Zanoni, additional, Giuseppe, Patuzzo, additional, Givaty, Gili, additional, Guilherme, Luiza, additional, Hammerstad, Sara Salehi, additional, Hodak, Emillia, additional, Hooks, John J., additional, Iaccarino, L., additional, Invernizzi, Pietro, additional, Israeli, Eitan, additional, Jamin, Christophe, additional, Janket, Sok-Ja, additional, Jarčuška, Peter, additional, Jones, Rodney P., additional, Kalil, Jorge, additional, Kanasi, Eleni, additional, Kivity, Shaye, additional, Konikoff, Tom, additional, Kozáková, D., additional, Krause, Ilan, additional, Lerner, Aaron, additional, Lidar, Merav, additional, Ling, Eduard, additional, Mahajna, Hussein, additional, Mahroum, Naim, additional, Maoz-Segal, Ramit, additional, Marinho, António, additional, Marshall, Trevor G., additional, Martinelli, Maria, additional, Marzia, Dolcino, additional, Mavragani, Clio P., additional, Mendonça, Teresa, additional, Miller, Stephen D., additional, Mimouni, Daniel, additional, Monteiro, Marta, additional, Moudgil, Kamal D., additional, Moulton, Vaishali R., additional, Moutsopoulos, Haralampos M., additional, Nagpal, Kamalpreet, additional, Neves, Esmeralda, additional, Nussenblatt, Robert, additional, Ollech, Ayelet, additional, Palma, L., additional, Pasoto, Sandra Gofinet, additional, Pella, Daniel, additional, Pereira, Cláudia, additional, Perricone, Carlo, additional, Petríková, Jana, additional, Proal, Amy D., additional, Rashid, Taha, additional, Reif, Shimon, additional, Renaudineau, Yves, additional, Ribeiro, Francinne Machado, additional, Rigante, Donato, additional, Rigopoulou, Eirini I., additional, Rose, Noel R., additional, Rosário, Cristina, additional, Rovenský, J., additional, Sakkas, Lazaros I., additional, Sarzi-Puttini, Piercarlo, additional, Seguro, Luciana Parente Costa, additional, Semino, Margherita, additional, Shoenfeld, Yehuda, additional, Silva, S., additional, Simonin, Laurent, additional, Smyk, Daniel S., additional, Sousa, Rita Catarina Medeiros, additional, Stagnaro, C., additional, Steere, Allen C., additional, Strle, Klemen, additional, Tektonidou, Maria G., additional, Tishler, Moshe, additional, Tomer, Yaron, additional, Toubi, Elias, additional, Tsokos, George C., additional, Vadasz, Zahava, additional, Valesini, Guido, additional, Vasconcelos, Carlos, additional, Vasconcelos, Júlia, additional, Vassilopoulos, Dimitrios, additional, Venkatesha, Shivaprasad H., additional, Vento, Sandro, additional, Viale, Christophe, additional, Villanueva, Ronald, additional, Vita, Pedro, additional, Wilson, Clyde, additional, Youinou, Pierre, additional, Záňová, E., additional, Zandman-Goddard, Gisele, additional, and Zen, M., additional

Published
2015
Full Text
View/download PDF

157. Somatic Mutations and the Risk of Undifferentiated Autoinflammatory Disease in MDS: An Under-Recognized but Prognostically Important Complication

Author

Watad, Abdulla, Kacar, Mark, Bragazzi, Nicola Luigi, Zhou, Qiao, Jassam, Miriam, Taylor, Jan, Roman, Eve, Smith, Alexandra, Jones, Richard A., Amital, Howard, Cargo, Catherine, McGonagle, Dennis, and Savic, Sinisa

Abstract

Objectives: We theorized that myelodysplastic syndrome (MDS) with somatic mutations and karyotype abnormalities are associated with autoinflammation, and that the presence of autoinflammatory disease affected prognosis in MDS. Methods: One hundred thirty-four MDS patients were assessed for the prevalence of autoinflammatory complications and its link with karyotypes and somatic mutation status. Autoinflammatory complications were described either as well-defined autoinflammatory diseases (AD) or undifferentiated “autoinflammatory disease” (UAD) (defined as CRP over 10.0 mg/L on five consecutive occasions, taken at separate times and not explained by infection). Several patient characteristics including demographic, clinical, laboratory, cytogenetics charts, and outcomes, were compared between different groups. Results: Sixty-two (46.3%) patients had an autoinflammatory complication manifesting as arthralgia (43.5% vs. 23.6%, p = 0.0146), arthritis (30.6% vs. 15.3%, p = 0.0340), skin rash (27.4% vs. 12.5%, p = 0.0301), pleuritis (14.5% vs. 4.2%, p = 0.0371) and unexplained fever (27.4% vs. 0%, p < 0.0001). AD were found in 7.4% of MDS patients (with polymyalgia rheumatic being the most frequently one). Classical autoimmune diseases were found only in 4 MDS patients (3.0%). Transcription factor pathway mutations (RUNX1, BCOR, WTI, TP53) (OR 2.20 [95%CI 1.02–4.75], p = 0.0451) and abnormal karyotypes (OR 2.76 [95%CI 1.22–6.26], p = 0.0153) were associated with autoinflammatory complications. Acute leukaemic transformation was more frequent in MDS patients with autoinflammatory features than those without (27.4% vs. 9.7%, p = 0.0080). Conclusions: Autoinflammatory complications are common in MDS. Somatic mutations of transcription factor pathways and abnormal karyotypes are associated with greater risk of autoinflammatory complications, which are themselves linked to malignant transformation and a worse prognosis.

Published
2021

160. Fibromyalgia position paper

Author

Sarzi-Puttini, Piercarlo, primary, Giorgi, Valeria, additional, Atzeni, Fabiola, additional, Gorla, Roberto, additional, Kosek, Eva, additional, Choy, Ernest H., additional, Bazzichi, Laura, additional, Häuser, Winfred, additional, Ablin, Jacob N., additional, Aloush, Valerie, additional, Buskila, Dan, additional, Amital, Howard, additional, Da Silva, Jose A.P., additional, Perrot, Serge, additional, Morlion, Bart, additional, Polati, Enrico, additional, Schweiger, Vittorio, additional, Coaccioli, Stefano, additional, Varrassi, Giustino, additional, Di Franco, Manuela, additional, Torta, Riccardo, additional, Øien Forseth, Karin Maria, additional, Mannerkorpi, Kaisa, additional, Salaffi, Fausto, additional, Di Carlo, Marco, additional, Cassisi, Gianniantonio, additional, and Batticciotto, Alberto, additional

Published
2021
Full Text
View/download PDF

161. Diagnostic and therapeutic care pathway for fibromyalgia

Author

Sarzi-Puttini, Piercarlo, primary, Giorgi, Valeria, additional, Atzeni, Fabiola, additional, Gorla, Roberto, additional, Kosek, Eva, additional, Choy, Ernest H., additional, Bazzichi, Laura, additional, Häuser, Winfred, additional, Ablin, Jacob N., additional, Aloush, Valerie, additional, Buskila, Dan, additional, Amital, Howard, additional, Da Silva, Jose A.P., additional, Perrot, Serge, additional, Morlion, Bart, additional, Polati, Enrico, additional, Schweiger, Vittorio, additional, Coaccioli, Stefano, additional, Varrassi, Giustino, additional, Di Franco, Manuela, additional, Torta, Riccardo, additional, Øien Forseth, Karin Maria, additional, Mannerkorpi, Kaisa, additional, Salaffi, Fausto, additional, Di Carlo, Marco, additional, Cassisi, Gianniantonio, additional, and Batticciotto, Alberto, additional

Published
2021
Full Text
View/download PDF

162. Autoimmune dysautonomia in women with silicone breast implants

Author

Halpert, Gilad, primary, Watad, Abdulla, additional, Tsur, Avishai M., additional, Dotan, Arad, additional, Quiros-Lim, Hector Enrique, additional, Heidecke, Harald, additional, Gilburd, Boris, additional, Haik, Josef, additional, Levy, Yair, additional, Blank, Miri, additional, Amital, Howard, additional, and Shoenfeld, Yehuda, additional

Published
2021
Full Text
View/download PDF

165. The mosaic of autoimmunity-A taste for more. The 12th international congress of autoimmunity 2021 (AUTO12) virtual

Author

Mahroum, Naim, Zoubi, Magdi, Lavine, Noy, Ohayon, Aviran, Amital, Howard, and Shoenfeld, Yehuda

Subjects
HLA, SARS-CoV-2, COVID-19, Autoimmunity, AUTO12, Autoantibodies
Abstract

Notwithstanding the fact that the 12th international congress of autoimmunity (AUTO12) was held virtual this year, the number of the abstracts submitted and those presented crossed the thousand marks. Leading investigators and researchers from all over the world presented the latest developments of their research in the domain of autoimmunity and its correlation with various diseases. In terms of mechanisms of autoimmunity, an update on the mechanisms behind the association of autoimmunity with systemic diseases focusing on hyperstimulation was presented during AUTO12. In addition, a new mechanism of ASIA syndrome caused by an intrauterine contraceptive device was revealed demonstrating a complete resolution of symptoms following device removal. In regard to the correlation between autoimmunity and neurogenerative diseases, the loss of structural protein integrity as the trigger of immunological response was shown. Schizophrenia as well, and its correlation to pro-inflammatory cytokines was also addressed. Furthermore, and as it was said AUTO12 virtual due to COVID-19 pandemic, various works were dedicated to SARS-CoV-2 infection and COVID-19 in terms of autoimmune mechanisms involved in the pathogenesis, treatment and complications of COVID-19. For instance, the correlation between autoimmunity and the severity of COVID-19 was viewed. Moreover, the presence and association of autoantibodies in COVID-19 was also demonstrated, as well as the clinical outcomes of COVID-19 in patients with rheumatic diseases. Finally, immune-mediated reactions and processes secondary to SARS-CoV-2 vaccination was displayed. Due to the immense importance of all of the topics addressed and while several hundreds of works were presented which cannot be summed up in one paper, we aimed hereby to highlight some of the outstanding abstracts and presentations during AUTO12.

Published
2021

166. Systematic review and meta-analysis of tocilizumab therapy versus standard of care in over 15,000 COVID-19 pneumonia patients during the first eight months of the pandemic

Author

Mahroum, Naim, Watad, Abdulla, Bridgewood, Charlie, Mansour, Muhammad, Nasr, Ahmad, Hussein, Amr, Khamisy-Farah, Rola, Farah, Raymond, Gendelman, Omer, Lidar, Merav, Shoenfeld, Yehuda, Amital, Howard, Kong, Jude Dzevela, Wu, Jianhong, Bragazzi, Nicola Luigi, and McGonagle, Dennis

Subjects
COVID-19, Tocilizumab, Systematic Review and Meta-Analysis
Abstract

Background. Tocilizumab is an anti-IL-6 therapy widely adopted in the management of the so-called "cytokine storm" related to SARS-CoV-2 virus infection, but its effectiveness, use in relation to concomitant corticosteroid therapy and safety were unproven despite widespread use in numerous studies, mostly open label at the start of the pandemic. Methods: We performed a systematic review and meta-analysis of case-control studies utilising tocilizumab in COVID-19 on different databases (PubMed/MEDLINE/Scopus) and preprint servers (medRxiv and SSRN) from inception until 20 July 2020 (PROSPERO CRD42020195690). Subgroup analyses and meta-regressions were performed. The impact of tocilizumab and concomitant corticosteroid therapy or tocilizumab alone versus standard of care (SOC) on the death rate, need for mechanical ventilation, ICU admission and bacterial infections were assessed. Results. Thirty-nine studies with 15,531 patients (3657 cases versus 11,874 controls) were identified. Unadjusted estimates (n = 28) failed to demonstrate a protective effect of tocilizumab on survival (OR 0.74 ([95%CI 0.55-1.01], p = 0.057), mechanical ventilation prevention (OR 2.21 [95%CI 0.53-9.23], p = 0.277) or prevention of ICU admission (OR 3.79 [95%CI 0.38-37.34], p = 0.254). Considering studies with adjusted, estimated, tocilizumab use was associated with mortality rate reduction (HR 0.50 ([95%CI 0.38-0.64], p < 0.001) and prevention of ICU admission (OR 0.16 ([95%CI 0.06-0.43], p < 0.001). Tocilizumab with concomitant steroid use versus SOC was protective with an OR of 0.49 ([95%CI 0.36-0.65], p < 0.05) as was tocilizumab alone versus SOC with an OR of 0.59 ([95%CI 0.34-1.00], p < 0.001). Risk of infection increased (2.36 [95%CI 1.001-5.54], p = 0.050; based on unadjusted estimates). Conclusion: Despite the heterogeneity of included studies and large number of preprint articles, our findings from the first eight of the pandemic in over 15,000 COVID-19 cases suggested an incremental efficacy of tocilizumab in severe COVID-19 that were confirmed by subsequent meta-analyses of large randomized trials of tocilizumab. This suggests that analysis of case-control studies and pre-print server data in the early stages of a pandemic appeared robust for supporting incremental benefits and lack of major therapeutic toxicity of tocilizumab for severe COVID-19. Canadian Institutes of Health Research (CIHR)

Published
2021

168. Personality disorders and cause-specific mortality: a nationwide study of 2 million adolescents.

Author

Tiosano, Shmuel, Laur, Lucian, Tirosh, Amir, Furer, Ariel, Afek, Arnon, Fink, Noam, Derazne, Estela, Tzur, Dorit, Fruchter, Eyal, Ben-Yehuda, Ariel, Bader, Tarif, Amital, Howard, Szklo, Moyses, Weiser, Mark, and Twig, Gilad

Subjects
CARDIOVASCULAR disease related mortality, PERSONALITY disorders, CAUSES of death, CARDIOVASCULAR diseases risk factors, PATIENT aftercare, LIFESTYLES, ADOLESCENT health, DESCRIPTIVE statistics, LONGITUDINAL method, ADOLESCENCE
Abstract

Background: Personality disorders are prevalent in 6–10% of the population, but their risk for cause-specific mortality is unclear. The aim of the study was to assess the association between personality disorders diagnosed in late adolescence and all-cause as well as cause-specific (cardiovascular-related, external-related) mortality. Methods: We performed a longitudinal study on a historical prospective cohort based on nationwide screening prior to recruitment to the Israeli army. The study participants were 16–19-year-old persons who attended the army screening (medical and cognitive, including screening for psychiatric disorders) between 1967 and 2006. Participants were followed from 1967 till 2011. Results: The study included 2 051 606 subjects, of whom 1 229 252 (59.9%) were men and 822 354 (40.1%) were women, mean age 17.36 years. There were 55 508 (4.5%) men and 8237 (1.0%) women diagnosed with personality disorders. The adjusted hazard ratio (HRs) for coronary, stroke, cardiovascular, external-related causes and all-cause mortality among men with personality disorders were 1.34 (1.03–1.74), 1.82 (1.20–2.76), 1.45 (1.23–1.71), 1.41 (1.30–1.53) and 1.44 (1.36–1.51), respectively. The absolute rate difference for all-cause mortality was 56.07 and 13.19 per 105 person-years among men and women, respectively. Among women with personality disorders, the adjusted HRs for external-related causes and all-cause mortality were 2.74 (1.87–4.00) and 2.01 (1.56–2.58). Associations were already evident within 10 years of follow-up. Conclusions: Personality disorder in late adolescence is associated with increased risk of cardiovascular, external- and all-cause mortality. Increased cardiovascular mortality is evident before the age of 40 years and may point to the importance of lifestyle education already in youth. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

169. risk, predictors and outcomes of amyloidosis in ankylosing spondylitis: a longitudinal population-based cohort study.

Author

Kridin, Mouhammad, Kridin, Khalaf, Cohen, Arnon D, Amital, Howard, and Watad, Abdulla

Subjects
CAUSES of death, CHRONIC kidney failure, AMYLOIDOSIS, CONFIDENCE intervals, ANKYLOSING spondylitis, DISEASE incidence, CASE-control method, RISK assessment, DISEASE susceptibility, DESCRIPTIVE statistics, ODDS ratio, LOGISTIC regression analysis, LONGITUDINAL method, PROPORTIONAL hazards models, COMORBIDITY, DISEASE risk factors, DISEASE complications
Abstract

Objectives The risk of amyloidosis during the course of AS is yet to be firmly established. We aimed to evaluate the risks, predictors and prognostic outcomes of amyloidosis among patients with AS. Methods A population-based cohort study was conducted comparing AS patients (n  = 5911) with age-, sex- and ethnicity-matched control subjects (n  = 29 007) with regard to incident cases of amyloidosis. Hazard ratios (HRs) and odds ratios (ORs) were estimated by Cox regression and logistic regression analyses, respectively. Results The incidence rate of amyloidosis was 2.15 (95% CI 1.09, 2.82) and 0.35 (95% CI 0.16, 0.66) per 10 000 person-years among patients with AS and controls, respectively. The risk of incident amyloidosis was >6-fold higher among patients with AS relative to control subjects [adjusted HR 6.16 (95% CI 2.43, 15.62); P  < 0.001]. A higher comorbidity burden [OR 1.36 (95% CI 1.08, 1.73); P  = 0.010] was found to predict an increased susceptibility to amyloidosis in AS patients. Compared with other patients with AS, those with AS and comorbid amyloidosis had a 14-fold increased risk of end-stage renal disease necessitating dialysis [adjusted HR 14.7 (95% CI 2.0, 107.2); P  = 0.008], but comparable risk of all-cause mortality [adjusted HR 2.16 (95% CI 0.69, 6.71); P  = 0.174]. Conclusions Patients with AS are at an increased risk of amyloidosis. AS-associated amyloidosis is associated with an elevated risk of dialysis dependence. Awareness of the burden and consequences of this complication may be of help for rheumatologists managing patients with AS. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

174. List of Contributors

Author

Abu-Shakra, Mahmoud, primary, Alard, Jean-Eric, additional, Amital, Howard, additional, Andreoli, L., additional, Antico, Antonio, additional, Antonelli, Alessandro, additional, Aoki, Christopher A., additional, Arepally, Gowthami, additional, Asashima, Hiromitsu, additional, Atzeni, Fabiola, additional, Bagnasco, Marcello, additional, Barcellini, Wilma, additional, Bayry, Jagadeesh, additional, Bendtzen, Klaus, additional, Ben-Nun, Avraham, additional, Berden, Jo H.M., additional, Bernareggi, Davide, additional, Bertolaccini, Maria Laura, additional, Bizzaro, Nicola, additional, Bogdanos, Dimitrios, additional, Borghi, Maria O., additional, Bowlus, Christopher L., additional, Božič, Borut, additional, Calise, S. John, additional, Caneparo, Valeria, additional, Canevari, Silvana, additional, Carcamo, Wendy C., additional, Carp, Howard J.A., additional, Cavazzana, Ilaria, additional, Ceribelli, Angela, additional, Cervera, Ricard, additional, Chan, Edward K.L., additional, Chan, Happy, additional, Chan, Jason Y.F., additional, Chang, Christopher, additional, Chapple, Katie, additional, Chiang, Bor-Luen, additional, Chighizola, Cecilia B., additional, Christen, Urs, additional, Ciavarella, Teresa, additional, Cicardi, Marco, additional, Cines, Douglas B., additional, Eschler, Deirdre Cocks, additional, Conrad, Karsten, additional, Coutinho, Ester, additional, Crotti, Chiara, additional, Csernok, Elena, additional, Čuc čnik, Sasa, additional, Cugno, Massimo, additional, Cuker, Adam, additional, Czarnocka, Barbara, additional, de Andrea, Marco, additional, Dell’Oste, Valentina, additional, De Los Reyes Labitigan, Monalyn, additional, Dominguez, Yasmany, additional, Einav, Yulia, additional, Fallahi, Poupack, additional, Feist, Eugen, additional, Ferri, Clodoveo, additional, Figini, Mariangela, additional, Fisher, Benjamin A., additional, Franceschini, Franco, additional, Fredi, M., additional, Fritzler, Marvin J., additional, Gariglio, Marisa, additional, Gerosa, Maria, additional, Gershwin, M. Eric, additional, Giometto, Bruno, additional, Giuggioli, Dilia, additional, Godlewska, Marlena, additional, Gross, Wolfgang L., additional, Grossman, Chagai, additional, Gualtierotti, Roberta, additional, Hamann, Dörte, additional, Harel, Michal, additional, Hershko, Alon Y., additional, Hiepe, Falk, additional, Hodak, Emmilia, additional, Huda, Saif, additional, Hultman, Per, additional, Iizuka, Mana, additional, Invernizzi, Pietro, additional, Jamin, Christophe, additional, Juan, Manel, additional, Kallenberg, Cees G.M., additional, Kapsogeorgou, Efstathia K., additional, Karussis, Dimitrios, additional, Kaushansky, Nathali, additional, Kaveri, Srini V., additional, Kawakita, Satoru, additional, Kazatchkine, Michel D., additional, Khamashta, Munther A., additional, Khan, Farah, additional, Küpper, Jan-Heiner, additional, Kveder, Tanja, additional, Lacroix-Desmazes, Sébastien, additional, Lakota, Katja, additional, Landolfo, Santo, additional, Lang, Bethan, additional, Lazúrová, Ivica, additional, Le Meur, Yannick, additional, Lerner, Aaron, additional, Li, Yi, additional, Liberal, Rodrigo, additional, Lidar, Merav, additional, Linington, Christopher, additional, Lima, Breno R., additional, Lleo, Ana, additional, Lopez, Luis R., additional, Maddison, Paul, additional, Mahler, Michael, additional, Matsumoto, Isao, additional, Matsuura, Eiji, additional, Meroni, Pier Luigi, additional, Mieli-Vergani, Giorgina, additional, Mimouni, Daniel, additional, Mrak-Poljsak, Katjusa, additional, Muller, Sylviane, additional, Muratori, Luigi, additional, Naguwa, Stanley M., additional, Naparstek, Yaakov, additional, Nobile-Orazio, Eduardo, additional, Nussenblatt, Robert B., additional, Pasvolsky, Oren, additional, Patil, Veerupaxagouda, additional, Paz, Damien Luque, additional, Paz, Ziv, additional, Pelizza, Federica, additional, Penatti, Alessandra, additional, Pengo, Vittorio, additional, Perricone, Carlo, additional, Perricone, Roberto, additional, Pers, Jacques-Olivier, additional, Petríková, Jana, additional, Petrou, Panayiota, additional, Piantoni, S., additional, Pietropaolo, Massimo, additional, Pittock, Sean J., additional, Pollard, K. Michael, additional, Pregnolato, Francesca, additional, Pura, Mikuláš, additional, Putterman, Chaim, additional, Radice, Antonella, additional, Raschi, Elena, additional, Ravindranath, Mepur H., additional, Reeves, Westley H., additional, Renaudineau, Yves, additional, Rinaldi, Maurizio, additional, Roggenbuck, Dirk, additional, Ronda, Nicoletta, additional, Rose, Noel R., additional, Rosenberg, Nurit, additional, Rozman, Blaž, additional, Ruffatti, Amelia, additional, Sarzi-Puttini, Piercarlo, additional, Satoh, Minoru, additional, Sciascia, Savino, additional, Scofield, R. Hal, additional, Sebastiani, Marco, additional, Selmi, Carlo, additional, Nida Sen, H., additional, Shenkman, Boris, additional, Shoenfeld, Yehuda, additional, Sinico, Renato Alberto, additional, Smeenk, Ruud J.T., additional, Sodin-Semrl, Snezna, additional, Sperling, Mark A., additional, Steenholdt, Casper, additional, Stöcker, Winfried, additional, Strassburg, Christian P., additional, Suffritti, Chiara, additional, Sumida, Takayuki, additional, Tampoia, Marilina, additional, Tedeschi, Alberto, additional, Tedesco, Francesco, additional, Terasaki, Paul I., additional, Tincani, Angela, additional, Tomer, Yaron, additional, Tonutti, Elio, additional, Toothaker, Thomas B., additional, Tozzoli, Renato, additional, Tsokos, George C., additional, Tsuboi, Hiroto, additional, Tzioufas, Athanasios G., additional, Ulmansky, Rina, additional, Usuki, Seigo, additional, Vaknin-Dembinsky, Adi, additional, van der Vlag, Johan, additional, Vergani, Diego, additional, Villalta, Danilo, additional, Vincent, Angela, additional, Weiner, Maya Ram, additional, Wener, Mark H., additional, Wiik, Allan, additional, Witte, Torsten, additional, Yang, Li-Jun, additional, Yang, Yao-Hsu, additional, Youinou, Pierre, additional, Yu, Hsin-Hui, additional, Yu, Robert K., additional, Zandman-Goddard, Gisele, additional, Zanella, Alberto, additional, Zanichelli, Andrea, additional, Zavdy, Ofir, additional, Zhuang, Haoyang, additional, and Zigon, Polona, additional

Published
2014
Full Text
View/download PDF

176. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination

Author

Watad, Abdulla, primary, De Marco, Gabriele, additional, Mahajna, Hussein, additional, Druyan, Amit, additional, Eltity, Mailam, additional, Hijazi, Nizar, additional, Haddad, Amir, additional, Elias, Muna, additional, Zisman, Devy, additional, Naffaa, Mohammad E., additional, Brodavka, Michal, additional, Cohen, Yael, additional, Abu-Much, Arsalan, additional, Abu Elhija, Muhanad, additional, Bridgewood, Charlie, additional, Langevitz, Pnina, additional, McLorinan, Joanna, additional, Bragazzi, Nicola Luigi, additional, Marzo-Ortega, Helena, additional, Lidar, Merav, additional, Calabrese, Cassandra, additional, Calabrese, Leonard, additional, Vital, Edward, additional, Shoenfeld, Yehuda, additional, Amital, Howard, additional, and McGonagle, Dennis, additional

Published
2021
Full Text
View/download PDF

189. Automated processing of thermal imaging to detect COVID-19

Author

Brzezinski, Rafael Y., primary, Rabin, Neta, additional, Lewis, Nir, additional, Peled, Racheli, additional, Kerpel, Ariel, additional, Tsur, Avishai M., additional, Gendelman, Omer, additional, Naftali-Shani, Nili, additional, Gringauz, Irina, additional, Amital, Howard, additional, Leibowitz, Avshalom, additional, Mayan, Haim, additional, Ben-Zvi, Ilan, additional, Heler, Eyal, additional, Shechtman, Liran, additional, Rogovski, Ori, additional, Shenhar-Tsarfaty, Shani, additional, Konen, Eli, additional, Marom, Edith M., additional, Ironi, Avinoah, additional, Rahav, Galia, additional, Zimmer, Yair, additional, Grossman, Ehud, additional, Ovadia-Blechman, Zehava, additional, Leor, Jonathan, additional, and Hoffer, Oshrit, additional

Published
2020
Full Text
View/download PDF

193. Medical cannabis treatment for chronic pain: Outcomes and prediction of response

Author

Aviram, Joshua, primary, Pud, Dorit, additional, Gershoni, Tamar, additional, Schiff‐Keren, Bareket, additional, Ogintz, Miriam, additional, Vulfsons, Simon, additional, Yashar, Tamar, additional, Adahan, Haim‐Moshe, additional, Brill, Silviu, additional, Amital, Howard, additional, Goor‐Aryeh, Itay, additional, Robinson, Dror, additional, Green, Leslie, additional, Segal, Refael, additional, Fogelman, Yacov, additional, Tsvieli, Oren, additional, Yellin, Ben, additional, Vysotski, Yelena, additional, Morag, Ofir, additional, Tashlykov, Vadim, additional, Sheinfeld, Roee, additional, Goor, Ruth, additional, Meiri, David, additional, and Eisenberg, Elon, additional

Published
2020
Full Text
View/download PDF

195. Personality disorders and cause-specific mortality: a nationwide study of 2 million adolescents

Author

Tiosano, Shmuel, primary, Laur, Lucian, additional, Tirosh, Amir, additional, Furer, Ariel, additional, Afek, Arnon, additional, Fink, Noam, additional, Derazne, Estela, additional, Tzur, Dorit, additional, Fruchter, Eyal, additional, Ben-Yehuda, Ariel, additional, Bader, Tarif, additional, Amital, Howard, additional, Szklo, Moyses, additional, Weiser, Mark, additional, and Twig, Gilad, additional

Published
2020
Full Text
View/download PDF

197. The pathogenic role of circulating Hashimoto's Thyroiditis‐derived TPO‐positive IgG on fetal loss in naïve mice

Author

Borodina, Elena, primary, Katz, Itai, additional, Antonelli, Alessandro, additional, Gzgzyan, Alexander M., additional, Dzhemlikhanova, Liailia Kh, additional, Ostrinski, Yuri, additional, Niauri, Dariko, additional, Khizroeva, Jamilya, additional, Bitsadze, Victoria, additional, Makatsariya, Alexander, additional, Tincani, Angela, additional, Nalli, Cecilia, additional, Churilov, Leonid P., additional, Shovman, Ora, additional, Halpert, Gilad, additional, Blank, Miri, additional, Shoenfeld, Yehuda, additional, and Amital, Howard, additional

Published
2020
Full Text
View/download PDF

200. Environmental shedding of toxigenic Clostridioides difficile by asymptomatic carriers: A prospective observational study

Author

Gilboa, M., primary, Houri-Levi, E., additional, Cohen, C., additional, Tal, I., additional, Rubin, C., additional, Feld-Simon, O., additional, Brom, A., additional, Eden-Friedman, Y., additional, Segal, S., additional, Rahav, G., additional, Regev-Yochay, G., additional, Amital, Howard, additional, Beni, Sharon, additional, Ben-Zvi, Ilan, additional, Blausov, Natasha, additional, Brom, Adi, additional, Cohen, Carmit, additional, Feld-Simon, Olga, additional, Fluss, Ronen, additional, Gilboa, Mayan, additional, Eden-Friedman, Yehudit, additional, Halevy, Shiraz, additional, Houri-Levi, Esther, additional, Hupert, Amit, additional, Jbarien, Amnah, additional, Keller, Naty, additional, Leibowitz, Avshalom, additional, Mayan, Haim, additional, Maizels, Leonid, additional, Meltzer, Eyal, additional, Pinas-Zade, Nani, additional, Rahav, Galia, additional, Raibman-Spector, Shir, additional, Regev-Yochay (PI), Gili, additional, Romiantsev, Marina, additional, Shachar, Dalit, additional, Sharif, Kassem, additional, Segal, Gadi, additional, Segal, Shoshi, additional, Segev, Amitai, additional, Smollan, Gill, additional, Stienlauf, Shmuel, additional, Tal, Ilana, additional, Yonath, Hagit, additional, Zilberman-Daniels, Tal, additional, and Zimlichman, Eyal, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results